Brutalist Biotech

• Sanofi signs €545M deal to explore Formation’s JAK/SYK inhibitor in new indication (14h)
• BrightGene tops Novo drug in diabetes ahead of Zepbound showdown (15h)
• Corxel, Sciwind post GLP-1 data as China's obesity push gathers pace (15h)
• Leap expands layoffs to cover 75% of employees, scraps only clinical trial to save cash (15h)
• Compass points to psychedelic therapy's phase 3 depression win, but investors unimpressed (16h)

• Relentless innovation: Bold exploration in advancing therapeutic options for every patient, every discovery (9h)
• Top drug official at FDA reportedly set to exit next month (9h)
• Cidara stock soars as antiviral drug succeeds in flu study (11h)
• Novo abruptly ends obesity drug deal with Hims (12h)
• Compass’ big psychedelic study doesn’t impress investors (12h)

• Politics collide with science ahead of new ACIP meeting (7h)
• Amgen plans more gradual MariTide dosing in Phase 3 (7h)
• FDA approves AstraZeneca, Daiichi Sankyo's Datroway in EGFR-mutated lung cancer (8h)
• Roche plans to pit next-gen hemophilia A antibody against Hemlibra in Phase 3 (8h)
• Supreme Court asks DOJ to weigh in on Hikma ‘skinny label’ fight (12h)

• Washington's Policy Shifts Are Driving Capital Away From Life-Saving Research (19m)
• FDA Conditional Pathway Not Necessary, Rare Disease Experts Say, While Applauding Intent (24m)
• Acting CDER Head Becomes Latest in String of FDA Leaders to Leave Agency (12h)
• Lilly Takes Victory Lap on Oral Weight Loss Drug as Analysts Spot Safety Crack (12h)
• Exelixis Beats Bayer in Colorectal Cancer as Zanzalintinib Delivers ‘First Pivotal Success’ (14h)

Bio IT World

• Nanoneedle Patch Enables Non-Invasive Tissue Sampling Offering Spatiotemporal Insights (5d)
• Black Swan Initiative: Multi-Pronged Research Strategy Targets Multiple Myeloma Cure (6d)
• Pistoia Alliance’s FAIR Maturity Assessment Tool (7d)
• Veteran ‘Lord of the Flies’ Takes a Crack at Addiction (2w)
• NVIDIA, Novo Nordisk Collaborate to Bring AI Agents to Drug Discovery (2w)

• Cassidy calls to delay meeting of CDC’s vaccine panel in challenge to RFK Jr. (4h)
• Health insurers promise to reduce barriers to care under pressure from Trump administration (7h)
• GLP-1 drug helped type 1 diabetes patients keep healthy glucose levels and lose weight (8h)
• Vertex stem cell therapy spurs insulin independence (8h)
• The Senate’s version of Trump’s tax-cut bill threatens safety-net hospitals like ours (9h)

• NVIDIA Releases Agentic AI Blueprint for Literature Review and Target Discovery (4d)
• Nabla Raises $70M Series C to Expand Agentic AI Platform for Clinical Workflows (5d)
• Axiom Bio Releases Human Liver Toxicity Dataset with 130,000 Compounds to Advance AI-based Toxicity Prediction (5d)
• Xaira Publishes Largest Public Perturb-seq Atlas to Advance Virtual Cell Modeling (6d)
• Agenus and Noetik Partner to Develop AI-Based Biomarkers Using Virtual Cell Models (6d)

• Turning plastic into medicine: Closing the loop on pharma production (13h)
• Special Episode: The 2025 BIO International Convention (3d)
• Stem cell therapy: a potential cure for hearing loss? (4d)
• 10 cultured meat companies driving sustainable food in 2025 (5d)
• From undruggable to oral therapy: The rise of STAT6 degraders (5d)

• Brain Receptor Structure Revealed to Support Cerebellum Function Repair (2h)
• Scientific Data Crisis Holds Back CMC (6h)
• Rare Gene Mutation Delays Alzheimer’s by Damping Immune Cell Inflammatory Signaling (8h)
• Potency Assays in Cell and Gene Therapy: Strategies for Manufacturing and Regulatory Success (8h)
• Novel Molecule May Rival GLP-1 Agonists for Diabetes and Obesity Treatment (13h)

• Faith, Friendship and Finding Purpose After Breast Cancer (7h)
• A New Digital Platform Aims to Expand Access to Early Oncology Trials (9h)
• FDA Approves Datroway for EGFR-Mutated Advanced Lung Cancer (9h)
• Living My Best Life: A Family Beach Vacation After a Brain Tumor (11h)
• Spotlighting Pancreatic Cancer Disparities in Black Communities (12h)

Contract Pharma*

• Novo Nordisk Axes Relationship with Hims & Hers (8h)
• Celltrion Opens UK Headquarters in Uxbridge (14h)
• Why Project Management Is the Real Differentiator for CDMOs (14h)
• Cellular Origins, Johnson & Johnson Partner for CGT Robotics Manufacturing Platform (14h)
• Nutriband, Kindeva Complete Commercial Scale-up for Aversa Fentanyl (14h)

• NHS rolls out new initiative to identify pancreatic cancer earlier (17h)
• eXmoor and Signadori Bio enter cell therapy partnership (4d)
• Teva and Fosun Pharma partner on early-stage oncology drug (5d)
• FDA approves UroGen’s Zusduri to treat recurrent bladder cancer (6d)
• EDX medical partners with spire healthcare to advance disease diagnostics (1w)

• More Than 50 Health Plans Commit to Simplifying Prior Authorization (4h)
• Why This Former OpenAI Exec Is Urging Health Leaders to ‘Specialize in Empathy’ (5h)
• Vertex Pharma’s Type 1 Diabetes Cell Therapy Shows Potential to Achieve Insulin Independence (9h)
• The Overlooked Global Warming Cost We Can’t Ignore (14h)
• The Medicaid Reckoning: Era of Fiscal and Policy Flux (14h)

• Veolia opens PFAS removal plant in Delaware (8h)
• Crystals defy their symmetry to discern chiral light (10h)
• Researchers turn plastic into paracetamol (12h)
• How air pollution can cause kidney disease (13h)
• Draig Therapeutics flies out of stealth to treat depression (3d)

The Pharma Letter*

• Lilly’s oral GLP-1 shows no liver safety issues in Phase III diabetes trial (11h)
• Medicus Pharma appoints COO; updates on SKNJCT-003 (11h)
• European approval for argenx expands autoimmune footprint (11h)
• Despite topline trial success, Compass going in wrong direction (11h)
• Otsuka in-licenses Harbour BioMed’s HBM7020 (13h)

• Walking Through the First 3 Physician Visits for Patients with mHSPC (9h)
• Zanzalintinib/Atezolizumab Improves CRC Survival, Expands TKI's Role in Solid Tumors (9h)
• FDA Grants Accelerated Approval to Dato-DXd in Previously Treated EGFR+ NSCLC (10h)
• Pirtobrutinib Outperforms Standard Options in Relapsed/Refractory CLL/SLL (10h)
• Dr Muvner on Targeted Therapies in Prostate Cancer (11h)

• Novo Nordisk ends collaboration with US partner after two months (15h)
• GN gains market share among US veterans in May (15h)
• Trump's "most favored nation” policy puts pressure on EU pharma industry (16h)
• Eli Lilly expects results from obesity candidate in the third quarter (18h)
• Novo Nordisk presents detailed data on weight loss candidate cagrisema (19h)

• Hexanitrogen (7h)
• Stir Bars Can't Be Ignored (5d)
• AI Effects on Drug Patents (1w)
• Mirror Morphine (2w)
• Vaccine Advice, Vandalized (2w)

• NHS records to be harnessed in pancreatic cancer screening (15h)
• EU kicks off review of GSK's linerixibat in PBC (16h)
• Roche's Hemlibra follow-up set for phase 3 in haemophilia A (16h)
• ADA: Lilly makes its case for oral GLP-1 orforglipron (17h)
• ADA: Novo continues effort to rehabilitate CagriSema (19h)

• Study supports monovalent antibody in neuropsychiatric disease (16h)
• New discovery could advance drugs for diabetes and obesity (18h)
• New DDW Highlights podcast: 22 June 2025 (20h)
• What international reference pricing could mean for US drug costs (20h)
• DDW Highlights: 22 June 2025 (20h)

Google News Biotech

• Concord Biotech Shows Strong Performance Amid Technical Evaluation Adjustments - MarketsMojo (16m)
• Windlas Biotech Faces Technical Shift Amidst Mixed Market Signals and Growth Concerns - MarketsMojo (18m)
• Biotech breakthrough: UoH alumni launch strategic partnership - The Hans India (21m)
• The Impact of Recent Biotech Lawsuits on Investor Confidence - BNO News (22m)
• Top Executives Make Bold Moves with Moleculin Biotech Stock Purchases - TipRanks (2h)